Hypertriglyceridemia as a multidisciplinary problem of modern medicine
https://doi.org/10.17802/2306-1278-2020-9-4-114-123
Abstract
Acute pancreatitis is one of the most common gastrointestinal causes for hospitalization after acute appendicitis. Despite recent advances in the treatment methods, mortality from acute pancreatitis and its complications remains high. Hypertriglyceridemia is an underestimated cause of acute pancreatitis, accounting for 10% among other etiological factors. Timely diagnosis of hypertriglyceridemia, a personalized approach, and the selection of adequate lipid-lowering therapy allow reducing the risk of developing and/or preventing recurrent acute pancreatitis. The article presents the clinical case of a patient with recurrent pancreatitis and hypertriglyceridemia. Despite high levels of triglycerides and annual hospitalizations for recurrent pancreatitis, the patient has not received optimal treatment for a long time. Therefore, lipid-modifying therapy has not been prescribed and none dietary recommendations have been suggested, including the exclusion of alcoholic beverages. Structural changes in the pancreas (the formation of pseudocysts) and the progression of pancreatogenic diabetes have developed.
About the Authors
O. V. Tsygankova
The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences; Novosibirsk State Medical University
Russian Federation
Competing Interests: заявляет об отсутствии конфликта интересов
Russian Federation
Tsygankova Oksana V. - M.D., Ph.D., a senior researcher at the Laboratory of Clinical, Biochemical and Hormonal Studies of Therapeutic Diseases, the Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, Institute of Cytology and Genetics”, the Siberian Branch RAS; Professor at the Department of Emergency Therapy with Endocrinology and Occupational Pathology, Novosibirsk SMU.
175/1, Borisa Bogatkova, Novosibirsk, 630091; Krasny Prospect 52, Novosibirsk, 630091
Competing Interests: заявляет об отсутствии конфликта интересов
N. V. Ozhiganova
The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences
Russian Federation
Competing Interests: заявляет об отсутствии конфликта интересов
Russian Federation
Ozhiganova Natalya V. - a postgraduate student, a research assistant at the Laboratory of Gastroenterology.
175/1, Borisa Bogatkova, Novosibirsk, 630091
Competing Interests: заявляет об отсутствии конфликта интересов
V. V. Kastalap
Research Institute for Complex Issues of Cardiovascular Diseases; Federal State Budgetary Educational Institution of Higher Education “Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Competing Interests: входит в редакционную коллегию журнала «Комплексные проблемы сердечно-сосудистых заболеваний»
Russian Federation
Kashtalap Vasiliy V. - M.D., Ph.D., the Head of the Department of Clinical Cardiology RI for Complex Issues of Cardiovascular Diseases; Associate Professor at the Department of Cardiology and Cardiovascular Surgery, Kemerovo SMU.
6, Sosonoviy Blvd., Kemerovo, 650002; 22a, Voroshilova St., Kemerovo, 650029
Competing Interests: входит в редакционную коллегию журнала «Комплексные проблемы сердечно-сосудистых заболеваний»
S. S. Bayramova
The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences
Russian Federation
Competing Interests: заявляет об отсутствии конфликта интересов
Russian Federation
Bayramova Sabina S. - a research assistant at the Laboratory of Emergency Therapy.
175/1, Borisa Bogatkova, Novosibirsk, 630091
Competing Interests: заявляет об отсутствии конфликта интересов
L. D. Latyntseva
The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences
Russian Federation
Competing Interests: заявляет об отсутствии конфликта интересов
Russian Federation
Latyntseva Ludmila D. - Ph.D., the Head of the Therapeutic Department, a senior researcher at the Laboratory of Emergency Cardiology.
175/1, Borisa Bogatkova, Novosibirsk, 630091
Competing Interests: заявляет об отсутствии конфликта интересов
References
1. Leppaniemi A., Tolonen M., Tarasconi A., Segovia-Lohse H., Gamberini E., Kirkpatrick A.W. et al. WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019; 14: 27. doi.org/10.1186/s13017-019-0247-0
2. Mach F., Baigent C., Catapano A.L., Konstantinos K.C. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 1; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455.
3. Guo Y.Y., Li H.X., ZhangY., He W.H. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019 Feb; 27(147): 101-109.
4. Kubyshkin V.A., Zatevahin I.I. Bagnenko S.F. Ostryj pankreatit. Klinicheskie rekomendacii.Rossijskoe obshchestvo hirurgov. Associaciya gepatopankreatobiliarnyh hirurgov stran SNG. Moskwa; 2019 (In Russian)
5. Kiss L., Fur G., Matrai P., Hegyi P., Ivany E. The effect of serum triglyceride concentration on the outcome of acute pancreatitis : systematic review and meta-analysis. Sci Rep. 2018; 8(1): 14096. doi: 10.1038/s41598-018-32337-x.
6. Lloret Linares C., Pelletier A.L., Czernichow S., Vergnaud A.C., Bonnefont-Rousselot D., Levy P., Ruszniewski P., Bruckert E. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13-2. doi: 10.1097/MPA.0b013e31816074a1
7. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. doi:10.1186/s12933-015-0268-2
8. de Pretis N., Amodio A., Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018; 6(5): 649-655. doi:10.1177/2050640618755002
9. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T. et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Assocaition Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25; 73(24): 3168-3209. doi: 10.1016/j.jacc.2018.11.002.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106: 3143-3421
11. Berglund L., Brunzell J.D., Goldberg A.C., Goldberg I.J., Sacks F., Murad M.H., Stalenhoef A.F. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012; 97(9): 2969-89. doi: 10.1210/jc.2011-3213.
12. Shah A.S., Wilson D.P. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015; 9(5): S20-8. doi: 10.1016/j.jacl.2015.04.004
13. Sergienko I. V., Ansheles A.A., Kuharchuk V.V. Ateroskleroz i dislipidemii: Sovremennye aspekty patogeneza, diagnostiki i lecheniya. Moskwa: OOO «PatiSS»; 2017. (In Russian)
14. Pedragosa A., Merino J., Aranda J.L., Galiana J., Godoy D., Panisello J.M., Ascaso J.F., Civeira F., Masana L., Pedro-Botet J. Clinical profile of patients with very high hypertriglyceridemia from the Registry of Hypertriglyceridemia of the SpanishAtherosclerosis Society. Clin InvestigArterioscler. 2013; 25(1): 8-15. doi: 10.1016/j.arteri.2012.11.001
15. Yadav D., Pitchumoni C.S. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003 Jan; 36(1): 54-62.
16. Tsygankova O.V., Badin A.R., Starichkov A.A., Lozhkina N.G. Nealkogol'naya zhirovaya bolezn' pecheni - bolezn' civilizacii ili sindrom sovremennosti? RMZH. Medicinskoe obozrenie. 2018; 3: 23-28. (In Russian)
17. Barbarash N.A., Kuvshinov D.Y Nutrition and Cardiovascular Health. Complex Issues of Cardiovascular Diseases. 2017;(2):87-92. (In Russian) doi.org/10.17802/2306-1278-2017-2-87-92
18. Klop B., do Rego A.T., Cabezas M.C. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013 Aug; 24(4): 3216. doi: 10.1097/MOL.0b013e3283606845.
19. Ewald N., Kloer H.U. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl. 2012 Jun; 7: 31-5.
20. Lan J., Zhao Y., Dong F., Yan Z., Zheng W., Fan J., Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 6981.
21. Jacobson T.A., Glickstein S.B., Rowe J.D., Soni P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012; 6: 518.
22. Benimetskaya K.S., Makarenkova K.S., Tsygankova O.V., Latyntseva L.D., Astrakov S.V., Shakhtschneider E.V., Ragino Yu.I., Voevoda M.I. The lack of the effect of evolocumab in a young woman with familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2018; 1: 67-71. (In Russian)
23. Dewey F.E., Gusarova V., Dunbar R.L., O’Dushlaine C., Schurmann C., Gottesman O., et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3): 211-221. doi:10.1056/NEJMoa1612790
24. Gaudet D., Gipe D.A., Pordy R., Ahmad Z., Cuchel M., Shah P.K., Chyu K.Y., Sasiela W.J., Chan K.C., Brisson D., Khoury E., Banerjee P., Gusarova V., Gromada J., Stahl N., Yancopoulos G.D., Hovingh G.K. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377: 296-297. doi: 10.1056/NEJMc1705994.
25. Graham M.J., Lee R.G., Brandt T.A., Tai L.J., Fu W., Peralta R., Yu R., Hurh E., Paz E., McEvoy B.W., Baker B.F., Pham N.C., Digenio A., Hughes S.G., Geary R.S., Witztum J.L., Crooke R.M., Tsimikas S. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 2017; 377: 222-232. doi: 10.1056/NEJMoa1701329
26. Graham M.J., Lee R.G., Bell T.A. III, Fu W., Mullick A.E., Alexander V.J., Singleton W., Viney N., Geary R., Su J., Baker B.F., Burkey J., Crooke S.T., Crooke R.M. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112: 1479-1490. doi: 10.1161/CIRCRESAHA.111.300367
27. Paik J., Duggan S. Volanesorsen: First Global Approval. Drugs. 2019 Aug; 79(12): 1349-1354. doi: 10.1007/s40265-019-01168-z.
28. Jiao Y., Lu Y., Li X.Y. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015; 36(1): 44-50. doi:10.1038/aps.2014.116
Review
For citations:
Tsygankova O.V., Ozhiganova N.V., Kastalap V.V., Bayramova S.S., Latyntseva L.D. Hypertriglyceridemia as a multidisciplinary problem of modern medicine. Complex Issues of Cardiovascular Diseases. 2020;9(4):114-123. (In Russ.) https://doi.org/10.17802/2306-1278-2020-9-4-114-123
Views:
637
